Agitation in Alzheimer's Disease Dementia
Conditions
Brief summary
Difference between active and placebo as measured by changes from baseline to endpoint (Week 6) in the Cohen-Mansfield Agitation Inventory total score
Detailed description
EXV-802: Difference between active and placebo as measured by changes from baseline to endpoint (Week 6) in the Clinical Global Impression of Severity of Illness (CGI-S) score, as related to symptoms of agitation., EXV-802: Difference between active and placebo as measured by changes from baseline to endpoint (Week 6) in the NPI-C Caregiver Distress total score for agitation and aggression., EXV-802: Difference between active and placebo as measured by changes from baseline to endpoint (Week 6) in the NPI-C Irritability / Lability score., EXV-802: Difference between active and placebo as measured by changes from baseline to endpoint (Week 6) in the NPI-C Sleep Disorders score., EXV-802: Difference between active and placebo in frequency and severity of adverse events and clinically relevant changes in relevant safety endpoints e.g.: • Mini‐Mental State Examination (MMSE) • Columbia Suicide Severity Rating Scale (C-SSRS) score • Clinical laboratory values • Vital signs • Electrocardiograms (ECGs) • Physical examination findings, EXV-801: Difference between active and placebo as measured by changes from baseline to endpoint (Week 6) in CMAI, CGI-S, NPI-C, exploratory PD markers (BDNF), and blood-based biomarkers (analysis limited to descriptive statistics, including the effect size)., EXV-801: Difference between active and placebo in frequency and severity of adverse events and clinically relevant changes in relevant safety endpoints e.g.: • Mini‐Mental State Examination (MMSE) • Columbia Suicide Severity Rating Scale (C-SSRS) score • Clinical laboratory values • Vital signs • Electrocardiograms (ECGs) • Physical examination findings
Sponsors
Eligibility
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference between active and placebo as measured by changes from baseline to endpoint (Week 6) in the Cohen-Mansfield Agitation Inventory total score | — |
Secondary
| Measure | Time frame |
|---|---|
| EXV-802: Difference between active and placebo as measured by changes from baseline to endpoint (Week 6) in the Clinical Global Impression of Severity of Illness (CGI-S) score, as related to symptoms of agitation., EXV-802: Difference between active and placebo as measured by changes from baseline to endpoint (Week 6) in the NPI-C Caregiver Distress total score for agitation and aggression., EXV-802: Difference between active and placebo as measured by changes from baseline to endpoint (Week 6) in the NPI-C Irritability / Lability score., EXV-802: Difference between active and placebo as measured by changes from baseline to endpoint (Week 6) in the NPI-C Sleep Disorders score., EXV-802: Difference between active and placebo in frequency and severity of adverse events and clinically relevant changes in relevant safety endpoints e.g.: • Mini‐Mental State Examination (MMSE) • Columbia Suicide Severity Rating Scale (C-SSRS) score • Clinical laboratory values • Vital signs • Electrocardiog | — |